中国科学院机构知识库网格
Chinese Academy of Sciences Institutional Repositories Grid
首页 机构 成果 学者
  
  1. CAS IR Grid
  2. 上海药物研究所
  3. 中国科学院上海药物研究所
  4. 新药研究国家重点实验室
Glycogen synthase kinase 3 beta inhibition synergizes with PARP inhibitors through the induction of homologous recombination deficiency in colorectal cancer

文献类型：期刊论文

作者Zhang, Ning1,3; Tian, Yu-Nan1,3; Zhou, Li-Na1,3; Li, Meng-Zhu1,3; Chen, Hua-Dong1,3; Song, Shan-Shan1,3; Huan, Xia-Juan1,3; Bao, Xu-Bin1,3; Zhang, Ao2; Miao, Ze-Hong1,3
刊名CELL DEATH & DISEASE
出版日期2021-02-15
卷号12期号:2页码:18
ISSN号2041-4889
DOI10.1038/s41419-021-03475-4
通讯作者Miao, Ze-Hong(zhmiao@simm.ac.cn) ; He, Jin-Xue(jinxue_he@simm.ac.cn)
英文摘要Monotherapy with poly ADP-ribose polymerase (PARP) inhibitors results in a limited objective response rate (<= 60% in most cases) in patients with homologous recombination repair (HRR)-deficient cancer, which suggests a high rate of resistance in this subset of patients to PARP inhibitors (PARPi). To overcome resistance to PARPi and to broaden their clinical use, we performed high-throughput screening of 99 anticancer drugs in combination with PARPi to identify potential therapeutic combinations. Here, we found that GSK3 inhibitors (GSK3i) exhibited a strong synergistic effect with PARPi in a panel of colorectal cancer (CRC) cell lines with diverse genetic backgrounds. The combination of GSK3 beta and PARP inhibition causes replication stress and DNA double-strand breaks, resulting in increased anaphase bridges and abnormal spindles. Mechanistically, inhibition or genetic depletion of GSK3 beta was found to impair the HRR of DNA and reduce the mRNA and protein level of BRCA1. Finally, we demonstrated that inhibition or depletion of GSK3 beta could enhance the in vivo sensitivity to simmiparib without toxicity. Our results provide a mechanistic understanding of the combination of PARP and GSK3 inhibition, and support the clinical development of this combination therapy for CRC patients.
资助项目National Natural Science Foundation of China[81773764] ; National Natural Science Foundation of China[82073875] ; National Natural Science Foundation of China[82073865] ; Chinese Academy of Sciences[29201731121100101] ; Chinese Academy of Sciences[XDA12020104] ; Chinese Academy of Sciences[XDA12020109] ; Chinese Academy of Sciences[CASIMM0120185003] ; Science and Technology Commission of Shanghai Municipality[19QA1410900] ; State Key Laboratory of Drug Research ; SA-SIBS Scholarship Program
WOS研究方向Cell Biology
语种英语
WOS记录号WOS:000620643500006
出版者SPRINGERNATURE
源URL[http://119.78.100.183/handle/2S10ELR8/295781]  
专题新药研究国家重点实验室
通讯作者Miao, Ze-Hong; He, Jin-Xue
作者单位1.Chinese Acad Sci, Shanghai Inst Mat Med, Div Antitumor Pharmacol, State Key Lab Drug Res, Shanghai 201203, Peoples R China
2.Chinese Acad Sci, Shanghai Inst Mat Med, Dept Med Chem, CAS Key Lab Receptor Res, Shanghai 201203, Peoples R China
3.Univ Chinese Acad Sci, 19A Yuquan Rd, Beijing 100049, Peoples R China
推荐引用方式
GB/T 7714		 Zhang, Ning,Tian, Yu-Nan,Zhou, Li-Na,et al. Glycogen synthase kinase 3 beta inhibition synergizes with PARP inhibitors through the induction of homologous recombination deficiency in colorectal cancer[J]. CELL DEATH & DISEASE,2021,12(2):18.
APA Zhang, Ning.,Tian, Yu-Nan.,Zhou, Li-Na.,Li, Meng-Zhu.,Chen, Hua-Dong.,...&He, Jin-Xue.(2021).Glycogen synthase kinase 3 beta inhibition synergizes with PARP inhibitors through the induction of homologous recombination deficiency in colorectal cancer.CELL DEATH & DISEASE,12(2),18.
MLA Zhang, Ning,et al."Glycogen synthase kinase 3 beta inhibition synergizes with PARP inhibitors through the induction of homologous recombination deficiency in colorectal cancer".CELL DEATH & DISEASE 12.2(2021):18.

入库方式： OAI收割

来源：上海药物研究所

浏览0
下载0
收藏0
其他版本

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。